BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Identical twins study uncovers insights into multiple sclerosis mechanisms October 4, 2024 Blocking liver enzyme Caspase-2 may increase long-term cancer risk January 13, 2026 Physical activity essential at all stages of adult life November 25, 2024